During the poster session, Physiogenex will be presenting a study dealing with the effects of evolocumab, an anti-PCSK9 antibody, in the Golden Syrian hamster model.
Another study dealing with the effects of obeticholic acid on atherosclerosis and NASH in LDL-r KO mice will be presented by Dr. François Briand, Director of Research and Business Development, during the morning poster session on Tuesday, June the 12th (session# CS 3-10: Type 2 Diabetes: A Persistent Challenge).

If you wish to make an appointment during the meeting with Dr. François Briand to discuss about your drug development project, please contact us.

 

libero dolor. Aliquam diam quis, venenatis, Lorem ipsum id Aenean consequat.